Hanover Insurance (THG)

NYSEFinancialsInsurance - Property & CasualtySnapshot 2026-10-23

$237.73-0.78%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Hanover Insurance’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.4%

+10% or more+5%0%−5%−10% or less

19.50 → 19.57 EPS · FY ending Dec 31, 2027 · 5 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 5; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	1.56B
EPS	—	5.407
Annual ending 2026-12-31
Revenue	—	6.65B
EPS	—	20.454
Annual ending 2027-12-31
Revenue	—	6.95B
EPS	—	19.57

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Improve cash from operations above $300 million next quarter	A primary condition in Hanover Insurance's published investment case. The stated target is >=300 million USD.	Improving	Cash from operations stays below $200 million next quarter	Cash from operations: $212.3M FY2026-Q2; GAAP. Published target: >=300 million USD. Target period is not explicitly aligned with this observation. Source published Jul 29, 2026212,300,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 of last 3 quarters including 2026-Q2, Q1, and 2025-Q4. Cash from operations increased from $118.8M in 2026-Q1 to $212.3M in 2026-Q2. Net investment income grew 13.4% year-over-year in 2026-Q2, reflecting higher yields and strong cash flows. The trajectory shows progress in enhancing cash generation and investment income. Delivery assessment Oct 24, 2026
Increase operating income to at least $250 million next quarter	Operating income rose to $250 million.	Under Pressure	operating income falls below $186 million next quarter	Operating income: $251.9M FY2026-Q2; GAAP. Published target: >=250 million USD. Target period is not explicitly aligned with this observation. Source published Jul 29, 2026251,900,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 207c9893-ff6c-4575-9195-c4ced80a6372. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 of last 3 quarters including 2026-Q2, Q1, and 2025-Q4. Operating income remained strong, increasing slightly from $186.4M in 2025-Q1 to $189.2M in 2026-Q2. Combined ratio improved from 94.1% to 91.2%, reflecting enhanced underwriting profitability. The trajectory is delivering consistent improvement in operating income and underwriting results. Delivery assessment Oct 24, 2026
Implement $700 million share repurchase program fully	The company started a $700 million share buyback.	Intact	Buyback program is canceled or materially delayed	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 disclosures including 2026-Q2 and May 2026 press release. The company repurchased about 291,000 shares for $55 million in Q2 2026 and has $660 million remaining capacity under the $700 million authorization. The trajectory shows active execution of the repurchase program. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$19.57

$18.63 → $19.57 · observed estimates

FY2027 revenueUnavailable

$6.96B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$18.63	$6,957,938,220	8 / 5
2026-07-25	$18.63	$6,957,938,220	8 / 5
2026-07-26	$18.50	Unavailable	5 / 4
2026-07-27	$18.63	$6,957,938,220	8 / 5
2026-07-28	$18.63	$6,957,938,220	8 / 5
2026-07-29	$18.56	Unavailable	5 / 4
2026-07-30	$18.63	$6,957,938,220	8 / 5
2026-07-31	$19.20	Unavailable	8 / 4
2026-08-01	$19.02	Unavailable	5 / 3
2026-08-02	$19.20	Unavailable	8 / 4
2026-08-03	$19.18	Unavailable	5 / 3
2026-08-04	$19.18	Unavailable	5 / 3
2026-08-05	$19.18	Unavailable	5 / 3
2026-08-06	$19.18	Unavailable	5 / 3
2026-08-08	$19.18	Unavailable	5 / 3
2026-08-09	$19.18	Unavailable	5 / 3
2026-08-10	$19.18	Unavailable	5 / 3
2026-08-12	$19.48	Unavailable	8 / 4
2026-08-13	$19.48	Unavailable	8 / 4
2026-08-14	$19.18	Unavailable	5 / 3
2026-08-15	$19.18	Unavailable	5 / 3
2026-08-16	$19.18	Unavailable	5 / 3
2026-08-17	$19.18	Unavailable	5 / 3
2026-08-18	$19.18	Unavailable	5 / 3
2026-08-19	$19.18	Unavailable	5 / 3
2026-08-20	$19.47	Unavailable	5 / 3
2026-08-21	$19.47	Unavailable	5 / 3
2026-08-22	$19.47	Unavailable	5 / 3
2026-08-23	$19.47	Unavailable	5 / 3
2026-08-24	$19.47	Unavailable	5 / 3
2026-08-25	$19.47	Unavailable	5 / 3
2026-08-26	$19.47	Unavailable	5 / 3
2026-08-27	$19.47	Unavailable	5 / 3
2026-08-28	$19.47	Unavailable	5 / 3
2026-08-29	$19.47	Unavailable	5 / 3
2026-08-30	$19.47	Unavailable	5 / 3
2026-08-31	$19.47	Unavailable	5 / 3
2026-09-01	$19.47	Unavailable	5 / 3
2026-09-02	$19.47	Unavailable	5 / 3
2026-09-03	$19.47	Unavailable	5 / 3
2026-09-04	$19.47	Unavailable	5 / 3
2026-09-05	$19.47	Unavailable	5 / 3
2026-09-06	$19.47	Unavailable	5 / 3
2026-09-07	$19.47	Unavailable	5 / 3
2026-09-08	$19.47	Unavailable	5 / 3
2026-09-09	$19.47	Unavailable	5 / 3
2026-09-10	$19.47	Unavailable	5 / 3
2026-09-11	$19.47	Unavailable	5 / 3
2026-09-12	$19.47	Unavailable	5 / 3
2026-09-13	$19.47	Unavailable	5 / 3
2026-09-14	$19.47	Unavailable	5 / 3
2026-09-15	$19.47	Unavailable	5 / 3
2026-09-16	$19.50	Unavailable	5 / 4
2026-09-17	$19.50	Unavailable	5 / 4
2026-09-18	$19.50	Unavailable	5 / 4
2026-09-19	$19.50	Unavailable	5 / 4
2026-09-20	$19.50	Unavailable	5 / 4
2026-09-21	$19.50	Unavailable	5 / 4
2026-09-22	$19.50	Unavailable	5 / 4
2026-09-23	$19.50	Unavailable	5 / 4
2026-09-24	$19.50	Unavailable	5 / 4
2026-09-25	$19.50	Unavailable	5 / 4
2026-09-26	$19.50	Unavailable	5 / 4
2026-09-27	$19.50	Unavailable	5 / 4
2026-09-28	$19.50	Unavailable	5 / 4
2026-09-29	$19.50	Unavailable	5 / 4
2026-09-30	$19.50	Unavailable	5 / 4
2026-10-01	$19.50	Unavailable	5 / 4
2026-10-02	$19.50	Unavailable	5 / 4
2026-10-03	$19.54	Unavailable	5 / 4
2026-10-04	$19.54	Unavailable	5 / 3
2026-10-05	$19.54	Unavailable	5 / 3
2026-10-06	$19.54	Unavailable	5 / 3
2026-10-07	$19.57	Unavailable	5 / 3
2026-10-08	$19.57	Unavailable	5 / 3
2026-10-09	$19.57	Unavailable	5 / 3
2026-10-10	$19.57	Unavailable	5 / 3
2026-10-11	$19.57	Unavailable	5 / 3
2026-10-12	$19.57	Unavailable	5 / 3
2026-10-13	$19.57	Unavailable	5 / 4
2026-10-14	$19.57	Unavailable	5 / 4
2026-10-15	$19.57	Unavailable	5 / 4
2026-10-16	$19.57	Unavailable	5 / 4
2026-10-17	$19.57	Unavailable	5 / 4
2026-10-18	$19.57	Unavailable	5 / 4
2026-10-19	$19.57	Unavailable	5 / 4
2026-10-20	$19.57	Unavailable	5 / 4
2026-10-21	$19.57	Unavailable	5 / 4
2026-10-22	$19.57	Unavailable	5 / 4
2026-10-23	$19.57	Unavailable	5 / 4
2026-10-24	$19.57	Unavailable	5 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	5	4
2026-06-01	4	4
2026-07-01	4	6
2026-08-01	2	6
2026-09-01	2	6
2026-10-01	2	6

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 6 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

OppenheimerOct 13

$260.00New observation · no comparable prior

Morgan StanleyOct 6 · prior Aug 19

$240.00 → $230.00-4.2%

$0$143.00$286.00

0 raises · 1 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Improve cash from operations above $300 million next quarterCash from operations: $212.3M
Increase operating income to at least $250 million next quarterPublished status: Under Pressure
Implement $700 million share repurchase program fullyDirect metric needs a verified mapping

Next proof point

Oct 28, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.0%Typical daily move · historical

Downside history

-10.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Hanover Insurance outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a financial-sector growth and underwriting story, with management execution currently on track. The thesis is on watch because recent performance trails its industry cohort, and confidence has eased from high to medium.

What's priced into Hanover Insurance

Valuation is above peers, while the expectations gap is close to neutral and the snapshot describes pricing as justified. That suggests the market is not assuming a sharply different outlook, but the premium leaves less room for weaker execution.

What the fundamentals likely do

Near term, earnings results have been positive, and management has continued to report premium growth, improving underwriting profitability, and steady operating income. Earnings quality remains fragile, however, and a guidance cut or a turn toward lower interest rates could weigh on the outlook; the snapshot puts near-term miss risk in the quiet tier.

What Hanover Insurance hinges on

Over the next few quarters, the thesis depends on management sustaining balanced growth and disciplined underwriting while continuing its share repurchase program. Guidance, interest-rate direction, and results from sector peers are key swing factors, with recent earnings beats offering support but not removing the risks.